MedTrace Logo

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

NCT00209027 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-06

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

Conditions

Interventions

OTHER

fMRI

fMRI scanning during behavioral reward task

DRUG

Aripiprazole

30 mg by mouth once daily

Sponsors & Collaborators

Principal Investigators

  • Erica Duncan, MD · Emory University/Atlanta VA Medical Center

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2010-12-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209027 on ClinicalTrials.gov